Nasal spray vs oral administration of bromocriptine: Pharmacology and effect on serum prolactin in puerperal women
- 8 Downloads
The oral administration of bromocriptine induces a variety of side-effects in about 50–70% of patients, the most common being nausea and vomiting, probably related to the local gastrointestinal effect of the drug. Nasal administration makes it possible to avoid intestinal and liver metabolism. This study compared the serum concentrations of bromocriptine and prolactin (PRL) in twenty puerperal women who had asked to discontinue breast feeding and were randomized to receive a single oral (2.5 mg) or nasal spray dose (0.8 mg) of bromocriptine. Serum bromocriptine and PRL concentrations were measured at various times before and after drug administration. At 15 min, the circulating concentrations of bromocriptine were about eight times higher after nasal than after oral administration; peak serum concentration (CMax) was reached respectively 45 min and 60 min after administration, and was about three times higher after nasal administration (314±102 pg/ml vs 112.30±34.47 pg/ml). The reduction in serum PRL concentrations was also more rapid in the nasally-treated group reaching the normal assay range of < 20 µg/l within two as against five hours post-administration. Four orally-treated patients complained of nausea; in the nasally-treated group, six patients reported only a mild endonasal burning that disappeared within a few minutes of administration. Our results suggest that the nasal administration of bromocriptine may lead to a reduction in the required overall dose and fewer gastrointestinal side-effects, and may therefore improve therapy compliance.
Key-wordsBromocriptine nasal route nasal administration oral administration hyperprolactinemia
Unable to display preview. Download preview PDF.
- 3.Metha A.E., Tolis G. Pharmacology of bromocriptine in health and disease. Drugs 77: 313, 1979.Google Scholar
- 4.Schran H.F., Bhuta S.I., Schwarz H.J., Thorner M.O. The pharmacokinetics of bromocriptine in man. In: Goldstein M., Calne D., Leiberman A., Thorner M.O. (Eds), Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects. Raven Press, New York, 1980, p. 125.Google Scholar
- 6.Rolland R. On ParlodeIR LAR and optimal treatment of hyperprolactinemia. In: Pepperel R.J. (Ed), New Aspects of dopamine agonist therapy in menstrual cycle disorders and infertility. The Parthenon Publishing Group, Casterton Hall, Carnforth, Lancs UK, 1990, p. 33.Google Scholar
- 11.Gopinath P.G., Gopinath R.D., Anad Kumar T.C. Target site of intranasally sprayed substances and their transport across the nasal mucosa: a new insight into intranasal route of drug delivery. Curr. Ther. Res. 23: 596, 1978.Google Scholar
- 12.Aeilig W.H., Nuesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int. J. Clin. Pharmacol. Res. 15: 106, 1977.Google Scholar
- 14.Jagannadha R.A., Moudal N.R., Li C.H. Beta-Endorphin: intranasal administration increases the serum prolactin level in monkeys. Int. J. Pept. Protein Res. 28: 546, 1986.Google Scholar